A Phase 1 interventional study of LC350189 200 mg in Gout and Hyperuricemia, sponsored by LG Chem. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-21.
Sponsored by LG Chem · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.
Among the 11 studies in Gout by LG Chem, this one is the 5th largest by enrollment, is one of 3 that started in 2019, is one of 8 in phase 1, and was the 5th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 37 across the 11 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Gout by LG Chem, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For healthy subjects only : The subject has normal renal function as determined by and calculated using the MDRD formula, or by 24-hour urine (CLcr) corrected for body size.
For subjects with renal impairment only
: The subject has mild, moderate, or severe renal impairment as determined by eGFR and calculated using the MDRD formula.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LC350189 200 mg
Drug: LC350189 200 mg
Drug: LC350189 200 mg
Drug: LC350189 200 mg
Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
AUC from time 0 to the last quantifiable concentration
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
AUC from time 0 to 24 hours post dose
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
AUC from time 0 to the end of the dosing interval at steady state
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Maximum observed plasma concentration
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Maximum observed plasma concentration at steady state
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Time to reach maximum observed plasma concentration
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Time to reach maximum observed plasma concentration at steady state
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Amount of drug excreted in urine (Ae) over each collection interval
Pharmacokinetic Assessments
Time frame: Before dosing on Days 1 through Day 8
Serum mean concentration over 24 hours
Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)
Time frame: Before dosing on Days 1 through Day 8
Maximum observed effect
Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)
Time frame: Before dosing on Days 1 through Day 8
Time to reach maximum effect
Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)
Time frame: Before dosing on Days 1 through Day 8
Incidence of adverse events
Safety
Time frame: Days 1 through Day 9 (end of study)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Sep 2020, 9 months.
Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 9 months is above that.
Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tigulixostat